(Q38108633)

29 August 2017

title

Dimethyl fumarate : a Janus-faced substance? (English)

1 reference

29 August 2017

Frieder Kees

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

22 May 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

1559-1567

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

29 August 2017

1 reference

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Enhanced number and activity of mitochondria in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Dimethylfumarate for psoriasis: more than a dietary curiosity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Psoriasis--recent advances in understanding its pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

An outbreak of furniture related dermatitis ('sofa dermatitis') in Finland and the UK: history and clinical cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Pharmacokinetics of oral fumarates in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine--preparation of S-substituted thiosuccinic acid esters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

In vitro pharmacokinetics of anti-psoriatic fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Inhibition of dendritic cell differentiation by fumaric acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Roles of reactive oxygen species and antioxidants in ovarian toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Effect of glutathione depletion on antioxidant enzymes in the epididymis, seminal vesicles, and liver and on spermatozoa motility in the aging brown Norway rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Antioxidant protection: A promising therapeutic intervention in neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Hormetic dietary phytochemicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Dual roles of Nrf2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

NRF2 and cancer: the good, the bad and the importance of context.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.804912

10.1517/14656566.2013.804912

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference